MYCN and neuroblastoma: Therefore, attempts to target the RAS pathway have focused on inhibiting its upstream or downstream effectors.MEK is an effector molecule of RAF, and in vitro experiments have found that neuroblastoma cell lines with mutations in the RAS family are sensitive to MEK inhibitors, but the presence of MYCN amplification leads to resistance to this class of drugs.